Purple Biotech (PPBT) has released an update.
Purple Biotech has identified a new serum biomarker, CEACAM1, which may significantly enhance the efficacy of their oncology therapeutic candidate, CM24, for treating metastatic pancreatic cancer. Patients with certain levels of this biomarker showed a 79% reduction in the risk of death and improved survival rates when treated with CM24 in combination with chemotherapy. As Purple Biotech continues its Phase 2 trials, this discovery could be a game-changer in personalizing cancer treatment and boosting patient outcomes.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.